Transcatheter correction of superior sinus venosus atrial septal defect: single centre experience with short- to medium-term outcomes.

INTRODUCTION

The superior sinus venosus atrial septal defect is situated immediately inferior to the junction of the superior caval vein (SCV) and the right atrium. It is usually associated with partial anomalous pulmonary venous drainage. Surgical correction used to be the only treatment option, but the transcatheter approach using a covered stent has recently evolved substantially.

PATIENTS AND

METHODS

This is a single-centre retrospective analysis of all patients who underwent transcatheter correction of sinus venosus atrial septal defect in our institution between January 2024 and January 2026. Data was collected from the Adult CHD multidisciplinary meeting records and patients' medical records. The hospital records, including case notes and other electronic data, were reviewed.

RESULTS

Five patients were treated with transcatheter correction of sinus venosus atrial septal defect and partial anomalous pulmonary venous drainage. All patients were adults with an age range of 30-61 years. Three were males. One patient received a 100-mm Optimus-CVS polytetrafluoroethylene (PTFE)-Covered Stent XXL, whereas all remaining 4 patients received an 80-mm stent. One patient received a second stent for a residual shunt. There were no mortalities or immediate adverse events. The follow-up period at the time of manuscript submission so far is 3-24 months, and no late complications have been observed.

CONCLUSIONS

Transcatheter closure of sinus venosus atrial septal defect is a feasible and safe procedure in selected patients with good results. The learning curve is still to be completed, and surgical options are not to be completely abolished.